Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05804669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

StatusCompleted
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Oct 2026 to Aug 25, 2026
    • Study completion date changed from estimate of Oct 2026 to Sep 8, 2026
    • Eligibility criteria expanded, about 10 words
    • Study description revised
  2. Enrollment closed, study ongoing
    • Enrollment target: estimated 18 to confirmed 19
    • Site details revised
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Interventions: CRN04894 (Drug) to atumelnant (Drug)
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 11 words
    v5
  5. Eligibility criteria expanded, about 5 wordsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria shortened, about 6 wordsv3
  2. Start date changed from estimate of Apr 2023 to Oct 12, 2023
    • Primary and study completion dates: Apr 2026 to Oct 2026
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])
Trial Details
NCT Number NCT05804669
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions
(from sponsor)		 Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Related terms ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov